Naguy Ahmed
Al-Manara CAP Centre, Kuwait Centre for Mental Health , Shuwaikh, Kuwait .
J Child Adolesc Psychopharmacol. 2017 Jun;27(5):471-472. doi: 10.1089/cap.2016.0182. Epub 2017 Mar 15.
Autism spectrum disorder (ASD) is commonly associated with a host of challenging behaviors. Pharmacotherapy is indicated if psychosocial and educational interventions fail. Atypical antipsychotics have the strongest evidence base so far, with both risperidone and aripiprazole being FDA approved. Unfortunately, their use is fraught with metabolic and neurohormonal side effects. In this study, the author is reporting on a case of syndromic ASD/moderate intellectual disability with severe behavioral component that failed multiple psychotropic trials and ultimately responded dramatically to sertindole. Sertindole reversed metabolic derangements and was highly tolerated. This is one of earliest cases to report use of sertindole in autism. This might open new venues in such complicated cases.
自闭症谱系障碍（ASD）通常与一系列具有挑战性的行为相关。如果心理社会和教育干预失败，则需进行药物治疗。非典型抗精神病药物目前有最有力的证据支持，利培酮和阿立哌唑均已获得美国食品药品监督管理局（FDA）批准。不幸的是，它们的使用充满了代谢和神经激素方面的副作用。在本研究中，作者报告了一例患有综合征性ASD/中度智力残疾且伴有严重行为问题的病例，该病例在多次精神药物试验中均失败，最终对舍吲哚产生了显著反应。舍吲哚逆转了代谢紊乱，且耐受性良好。这是最早报告在自闭症中使用舍吲哚的病例之一。这可能为这类复杂病例开辟新的途径。
